Data MATRIX, an eClinical software developer, has announced free access to its proprietary EDC system for sponsors running COVID-19 trials in 2020.
Recognizing the latest update of the World Health Organization with the total count of people diagnosed with coronavirus surpassing 200,000 over 8,000 of whom died, Data MATRIX’s team could not overlook the urgency which calls for the highest level of productivity and proficiency from the global life sciences community.
In response to the global outbreak of the pandemic the clinical data management software developer will provide its validated SaaS solution for clinical trials at zero cost for researchers to be able to obtain clean data and speed up the trials of such a vital value to the global community.
Given that timeline is of the highest value when dealing with pandemic, Data MATRIX EDC will provide researchers with the essential resources enabling immediate project start-up and deployment.
“During these times it is essential for everyone to practice compassion and humanity. We encourage businesses of various industries to pool their efforts and resources and do all they can in helping to combat the pandemic. We are more than happy to support researchers looking for a COVID-19 vaccine. Therefore, we are honored to provide our solutions to all the researchers and healthcare colleagues around the world to stop this unprecedented global threat. We want to step in simply because we can,” said Data MATRIX Founder, Dmitry Sharov.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.